"Regeneron Pharmaceuticals, Inc. Acquires 23andMe: Advancing Genetic Research and Personalized Healthcare"
Read "Regeneron Pharmaceuticals, Inc. Acquires 23andMe: Advancing Genetic Research and Personalized Healthcare" on WALY Radio
"Regeneron Pharmaceuticals, Inc. Acquires 23andMe: Advancing Genetic Research and Personalized Healthcare"
[!CDATA[Regeneron Pharmaceuticals, Inc. has entered into a definitive agreement to acquire 23andMe Holding Co., a prominent human genetics and biotechnology company. The agreement includes Regeneron's commitment to uphold 23andMe's privacy policies and comply with all relevant laws. The transaction, subject to court approval, involves Regeneron acquiring most of 23andMe's assets, including the Personal Genome Service and Total Health and Research Services, for $256 million. Regeneron will not acquire 23andMe's Lemonaid Health subsidiary, which will be wound down according to the agreement. Mark Jensen, Chair of the Special Committee of the Board of Directors of 23andMe, expressed satisfaction with the transaction, emphasizing the importance of maintaining customer privacy, choice, and consent regarding genetic data. Regeneron has also pledged to retain all employees of the acquired business units, ensuring the continuation of 23andMe's mission to provide insights into the human genome for health benefits. George D. Yancopoulos, M.D. Ph.D., co-Founder and Chief Scientific Officer of Regeneron, highlighted the company's commitment to genetic research and its track record of safeguarding personal genetic data through the Regeneron Genetics Center. Regeneron's acquisition of 23andMe signifies a strategic alignment between the two companies in advancing genetic research and personalized healthcare. By leveraging Regeneron's expertise in drug discovery and genetic research, 23andMe aims to enhance its consumer genetic services and empower individuals to make informed decisions about their health based on their DNA. The agreement underscores Regeneron's dedication to improving health outcomes through innovative medicines and genetic insights, while upholding the highest standards of data security and integrity for 23andMe customers. In conclusion, the acquisition of 23andMe by Regeneron represents a significant milestone in the field of genetic research and personalized medicine. The collaboration between these two leading biotechnology companies is poised to drive advancements in healthcare by leveraging genetic data to enhance understanding of human health and disease. Customers can expect continued privacy protections and data security measures as Regeneron and 23andMe work together to fulfill their shared mission of improving health outcomes through genetic insights and innovative treatments.]]